{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:19:39Z","timestamp":1779293979278,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to integrate artificial intelligence (AI)with heat shock protein 90 alpha (HSP90\u03b1)expression to improve patient selection and prognostic assessment in unresectable hepatocellular carcinoma (HCC)treated with transarterial chemoembolization (TACE). We retrospectively enrolled 2555 unresectable HCC patients treated between 2016 and 2021 at seven Chinese tertiary hospitals. Residual-based methods were used to define TACE benefit. Eight AI models revealed that HSP90\u03b1 expression, Barcelona Clinic Liver Cancer (BCLC)stage, and tumor size were key predictive factors for TACE benefit. A nomogram based on these three variables achieved an area under the receiver operating characteristic curve (AUC)of 0.901 in the validation cohort. For overall survival (OS), we developed 101 machine learning models. The StepCox[forward] plus random survival forest model showed the best performance. Its C-indices were 0.84, 0.70, and 0.78 in the training, internal validation, and external validation sets, respectively. In the internal validation set, the time-dependent AUCs for 1-, 2-, and 3\u2009year OS were 0.835, 0.821, and 0.776; in the external validation set, they were 0.854, 0.790, and 0.804. Integrating AI with HSP90\u03b1 enables robust identification of TACE-benefit candidates and accurate prognostic stratification in unresectable HCC.<\/jats:p>","DOI":"10.1038\/s41746-025-02281-y","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T03:32:57Z","timestamp":1766806377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Artificial intelligence-based personalized treatment strategies for unresectable hepatocellular carcinoma: integrating HSP90\u03b1 for prognosis and survival prediction"],"prefix":"10.1038","volume":"9","author":[{"given":"Ke","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianbin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zunyuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lexin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guixu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"2281_CR1","doi-asserted-by":"crossref","unstructured":"Moris, D. et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. CA: Cancer J Clin. 75, 498\u2013527 (2025).","DOI":"10.3322\/caac.70018"},{"key":"2281_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41575-024-01021-z","volume":"22","author":"YH Yeo","year":"2025","unstructured":"Yeo, Y. H. et al. Current and emerging strategies for the prevention of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 22, 173\u2013190 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2281_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 293\u2013313 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2281_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12072-022-10339-2","volume":"16","author":"K Su","year":"2022","unstructured":"Su, K. et al. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Hepatol. Int. 16, 858\u2013867 (2022).","journal-title":"Hepatol. Int."},{"key":"2281_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","volume":"11","author":"LA Dawson","year":"2025","unstructured":"Dawson, L. A. et al. Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial. JAMA Oncol. 11, 136\u2013144 (2025).","journal-title":"JAMA Oncol."},{"key":"2281_CR6","doi-asserted-by":"crossref","unstructured":"Xu, K. et al. Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma. Discov. Oncol. 16, 1081 (2025)","DOI":"10.1007\/s12672-025-02914-4"},{"key":"2281_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.972503","volume":"13","author":"K Su","year":"2022","unstructured":"Su, K. et al. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: a propensity score matching study. Front. Immunol. 13, 972503 (2022).","journal-title":"Front. Immunol."},{"key":"2281_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102367","volume":"67","author":"XK Wu","year":"2024","unstructured":"Wu, X. K. et al. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinicalMedicine 67, 102367 (2024).","journal-title":"EClinicalMedicine"},{"key":"2281_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/pro6.70003","volume":"9","author":"Y Wang","year":"2025","unstructured":"Wang, Y., Jian, W., Yuan, Z., Guan, F. & Carlson, D. Deep learning with attention modules and residual transformations improves hepatocellular carcinoma (HCC) differentiation using multiphase CT. Prec. Radiat. Oncol. 9, 13\u201322 (2025).","journal-title":"Prec. Radiat. Oncol."},{"key":"2281_CR10","unstructured":"Minami, T. et al. Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals. J. Hepatol. 24, S0168-8278(23)00424-5 (2023)."},{"key":"2281_CR11","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jhep.2020.05.052","volume":"73","author":"E Audureau","year":"2020","unstructured":"Audureau, E. et al. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. J. Hepatol. 73, 1434\u20131445 (2020).","journal-title":"J. Hepatol."},{"key":"2281_CR12","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.25814","volume":"56","author":"EG Giannini","year":"2012","unstructured":"Giannini, E. G. et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology (Baltimore, Md) 56, 1371\u20131379 (2012).","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"Jan","key":"2281_CR13","doi-asserted-by":"publisher","first-page":"20160524","DOI":"10.1098\/rstb.2016.0524","volume":"373","author":"SK Calderwood","year":"2018","unstructured":"Calderwood, S. K. Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands? Philos. Trans. R. Soc. Lond B. Biol. Sci. 373(Jan), 20160524 (2018).","journal-title":"Philos. Trans. R. Soc. Lond B. Biol. Sci."},{"issue":"Jan","key":"2281_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6489-0","volume":"20","author":"W Wei","year":"2020","unstructured":"Wei, W. et al. Diagnostic value of plasma HSP90\u03b1 levels for detection of hepatocellular carcinoma. BMC Cancer 20(Jan), 6 (2020).","journal-title":"BMC Cancer"},{"issue":"Oct","key":"2281_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ebiom.2017.09.007","volume":"24","author":"Y Fu","year":"2017","unstructured":"Fu, Y. et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter clinical trial. EBioMedicine 24(Oct), 56\u201363 (2017).","journal-title":"EBioMedicine"},{"key":"2281_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1007\/s12072-022-10391-y","volume":"16","author":"K Su","year":"2022","unstructured":"Su, K. et al. Heat-shock protein 90\u03b1 is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study. Hepatol. Int. 16, 1208\u20131219 (2022).","journal-title":"Hepatol. Int."},{"key":"2281_CR17","volume":"22","author":"Y He","year":"2023","unstructured":"He, Y. et al. Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma. J. Natl. Comprehensive Cancer Netw. JNCCN 22, e237069 (2023).","journal-title":"J. Natl. Comprehensive Cancer Netw. JNCCN"},{"key":"2281_CR18","doi-asserted-by":"publisher","first-page":"e1209","DOI":"10.1097\/SLA.0000000000003803","volume":"274","author":"YY Wang","year":"2021","unstructured":"Wang, Y. Y. et al. Development and validation of a nomogram to preoperatively estimate post-hepatectomy liver dysfunction risk and long-term survival in patients with hepatocellular carcinoma. Annal. surg. 274, e1209\u2013e1217 (2021).","journal-title":"Annal. surg."},{"key":"2281_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-021-01180-5","volume":"14","author":"L Liang","year":"2021","unstructured":"Liang, L. et al. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma. J. Hematol. Oncol. 14, 165 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2281_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jhep.2020.04.032","volume":"73","author":"M Serenari","year":"2020","unstructured":"Serenari, M. et al. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. J. Hepatol. 73, 855\u2013862 (2020).","journal-title":"J. Hepatol."},{"key":"2281_CR21","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/s12276-025-01486-1","volume":"57","author":"N Zhang","year":"2025","unstructured":"Zhang, N. et al. C1QL1 inhibits breast cancer through the HSP90\u03b1\/VCP-ERS\/UPR axis. Exp. Mol. Med. 57, 1308\u20131323 (2025).","journal-title":"Exp. Mol. Med."},{"key":"2281_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06196-w","volume":"23","author":"G Shen","year":"2025","unstructured":"Shen, G. et al. HSP90 co-regulates the formation and nuclear distribution of the glycolytic output complex to promote resistance and poor prognosis in gastric cancer patients. J. Transl. Med. 23, 172 (2025).","journal-title":"J. Transl. Med."},{"key":"2281_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s12033-024-01151-4","volume":"67","author":"PK Praveen Kumar","year":"2025","unstructured":"Praveen Kumar, P. K. et al. The role of HSP90 and rRAP1 targets on treatment in hepatocellular carcinoma. Mol. Biotechnol. 67, 1367\u20131381 (2025).","journal-title":"Mol. Biotechnol."},{"issue":"Sep","key":"2281_CR24","doi-asserted-by":"publisher","first-page":"e2125055","DOI":"10.1001\/jamanetworkopen.2021.25055","volume":"4","author":"WP Lin","year":"2021","unstructured":"Lin, W. P. et al. Development and validation of a model including distinct vascular patterns to estimate survival in hepatocellular carcinoma. JAMA Netw. Open 4(Sep), e2125055 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"Sep","key":"2281_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2021.07.009","volume":"155","author":"JC Wang","year":"2021","unstructured":"Wang, J. C. et al. Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. Eur. J. Cancer 155(Sep), 85\u201396 (2021).","journal-title":"Eur. J. Cancer"},{"issue":"Oct","key":"2281_CR26","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1007\/s00259-021-05328-w","volume":"48","author":"W Miao","year":"2021","unstructured":"Miao, W. et al. An FDG PET\/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur. J. Nucl. Med. Mol. Imaging 48(Oct), 3656\u20133665 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"Oct","key":"2281_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2025.04.017","volume":"83","author":"M Vithayathil","year":"2025","unstructured":"Vithayathil, M. et al. Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma. J. Hepatol. 83(Oct), 959\u2013970 (2025).","journal-title":"J. Hepatol."},{"key":"2281_CR28","doi-asserted-by":"publisher","unstructured":"Hao, S. et al. Identification and validation of an explainable machine learning model for hepatocellular carcinoma with high-risk: a retrospective multicenter cohort study. Int. J. Surg. https:\/\/doi.org\/10.1097\/JS9.0000000000003480 (2025)","DOI":"10.1097\/JS9.0000000000003480"},{"issue":"Mar","key":"2281_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119680","volume":"1871","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. HSP90a promotes the resistance to oxaliplatin in HCC through regulating IDH1-induced cell competition. Biochim. Biophys. Acta Mol. Cell Res. 1871(Mar), 119680. https:\/\/doi.org\/10.1016\/j.bbamcr.2024.119680 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"2281_CR30","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2147\/JHC.S415843","volume":"10","author":"H Li","year":"2023","unstructured":"Li, H. et al. PD-1inhibitors combined with antiangiogenic therapy with or without transarterial chemoembolization in the treatment of hepatocellular carcinoma: a propensity matching analysis. J. hepatocell. carcinoma 10, 1257\u20131266 (2023).","journal-title":"J. hepatocell. carcinoma"},{"key":"2281_CR31","doi-asserted-by":"crossref","unstructured":"Li, L. et al. Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria. J. Immunother. Cancer. 13, e010035 (2025);","DOI":"10.1136\/jitc-2024-010035"},{"key":"2281_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"ZC Jin","year":"2024","unstructured":"Jin, Z. C. et al. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine 72, 102622 (2024).","journal-title":"EClinicalMedicine"},{"key":"2281_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/pro6.70001","volume":"9","author":"H Luo","year":"2025","unstructured":"Luo, H., Yang, C., Yue, J. & Ge, H. Consensus statement on the exploration of clinical translation and application of electron ultra-high dose rate FLASH radiotherapy. Prec. Radiat. Oncol. 9, 4\u201312 (2025).","journal-title":"Prec. Radiat. Oncol."},{"key":"2281_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/pro6.70007","volume":"9","author":"W Liao","year":"2025","unstructured":"Liao, W., Zhao, Y. & Zhang, S. The evolution of prophylactic neck irradiation in nasopharyngeal carcinoma: Changing concepts and irradiation ranges. Prec. Radiat. Oncol. 9, 61\u201368 (2025).","journal-title":"Prec. Radiat. Oncol."},{"issue":"May","key":"2281_CR35","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2147\/JHC.S521378","volume":"12","author":"K Su","year":"2025","unstructured":"Su, K. et al. Machine Learning Radiomics for Predicting Response to MR-Guided Radiotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study. J Hepatocell Carcinoma 12(May), 933\u2013947 (2025).","journal-title":"J Hepatocell Carcinoma"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02281-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02281-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02281-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:25:04Z","timestamp":1769689504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02281-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2281"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-02281-y","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}